---
title: "City Therapeutics hits 52-week low"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304474029.md"
description: "City Therapeutics fell 1.65% to US$16.14. Down 26.47% over five sessions and down 9.56% from IPO price."
datetime: "2026-11-05T14:31:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304474029.md)
  - [en](https://longbridge.com/en/news/304474029.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304474029.md)
generator: "portal-rs"
---

# City Therapeutics hits 52-week low

City Therapeutics (CTY.US) slipped nearly **2%** during regular trading to **$16.14**, hitting a 52-week low intraday.

The stock is down 26.47% over the past five sessions and down 9.56% from its IPO price. It sits 32.41% below its 52-week high of US$23.88.

The Nasdaq Composite is down 2.65% over the past five sessions and up 9.68% year to date.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [CTY.US](https://longbridge.com/en/quote/CTY.US.md)

## Related News & Research

- [QUOTES-People react to US AI chip curbs that threaten data centre boom](https://longbridge.com/en/news/305767058.md)
- [Jim Cramer says Nvidia’s leadership shake-up won’t derail the AI trade](https://longbridge.com/en/news/305736094.md)
- [Marvell outlines custom HBM design approach at 2026 OCP Global Summit](https://longbridge.com/en/news/305857411.md)
- [Nvidia has lost $2 trillion in value. Here's what options traders expect from earnings](https://longbridge.com/en/news/305815593.md)
- [MPs ask what the break clause was for as Palantir wins two more years in the NHS](https://longbridge.com/en/news/305803837.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**